全文获取类型
收费全文 | 13130篇 |
免费 | 886篇 |
国内免费 | 66篇 |
专业分类
耳鼻咽喉 | 73篇 |
儿科学 | 312篇 |
妇产科学 | 341篇 |
基础医学 | 1816篇 |
口腔科学 | 447篇 |
临床医学 | 1213篇 |
内科学 | 2710篇 |
皮肤病学 | 215篇 |
神经病学 | 1478篇 |
特种医学 | 475篇 |
外国民族医学 | 1篇 |
外科学 | 1690篇 |
综合类 | 31篇 |
现状与发展 | 1篇 |
一般理论 | 8篇 |
预防医学 | 1111篇 |
眼科学 | 179篇 |
药学 | 831篇 |
中国医学 | 49篇 |
肿瘤学 | 1101篇 |
出版年
2023年 | 128篇 |
2022年 | 261篇 |
2021年 | 459篇 |
2020年 | 285篇 |
2019年 | 432篇 |
2018年 | 486篇 |
2017年 | 391篇 |
2016年 | 452篇 |
2015年 | 417篇 |
2014年 | 530篇 |
2013年 | 687篇 |
2012年 | 988篇 |
2011年 | 969篇 |
2010年 | 517篇 |
2009年 | 483篇 |
2008年 | 764篇 |
2007年 | 729篇 |
2006年 | 735篇 |
2005年 | 680篇 |
2004年 | 636篇 |
2003年 | 573篇 |
2002年 | 472篇 |
2001年 | 205篇 |
2000年 | 165篇 |
1999年 | 187篇 |
1998年 | 91篇 |
1997年 | 97篇 |
1996年 | 61篇 |
1995年 | 50篇 |
1994年 | 47篇 |
1993年 | 32篇 |
1992年 | 98篇 |
1991年 | 111篇 |
1990年 | 86篇 |
1989年 | 85篇 |
1988年 | 64篇 |
1987年 | 67篇 |
1986年 | 75篇 |
1985年 | 59篇 |
1984年 | 60篇 |
1983年 | 23篇 |
1982年 | 28篇 |
1981年 | 25篇 |
1979年 | 29篇 |
1978年 | 27篇 |
1977年 | 21篇 |
1976年 | 20篇 |
1974年 | 24篇 |
1973年 | 19篇 |
1972年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
31.
32.
The octadecyl rhodamine (R18) fluorescent dequenching assay was used to examine membrane fusion between mumps virus and mammalian cells. Rapid fluorescent dequenching, indicative of membrane fusion, was observed when labeled mumps virus was mixed with either ghost erythrocytes or CV-1 cells. After 15 min a saturation limit of 18 virus per erythrocyte ghost and 6400 virus per CV-1 cell was observed. Fetuin was found to inhibit virus fusion, suggesting a role for sialic acid in virus binding to the cells. Two dequenching processes were observed of which the faster process is thought to be membrane fusion and the second process is thought to be probe proximal transfer. 相似文献
33.
Marco Montorsi Guido Torzilli Uberto Fumagalli Stefano Bona Riccardo Rosati Matilde de Simone Vittorio Rovati Franco Mosca Carlo Filice 《HPB surgery》1994,8(2):89-94
The increased use of Ultrasonography (US) has led to increased detection of simple hepatic cysts.
For symptomatic cysts treatment is necessary. Until some years ago surgery was the only
therapy. We have treated a large number of patients with Percutaneous Alcohol Sclerotherapy
(PAS) and evaluated retrospectively the efficacy of this approach.Data on 21 patients with symptomatic simple hepatic cysts were reviewed retrospectively.
Cysts had a mean diameter of 9 cm (range: 7–15 cm). PAS was always performed under local
anesthesia and US guidance. 25% of the volume was replaced with 95% ethanol and then
completely aspirated after 20–30 minutes.No complications or deaths occurred. In all patients symptoms disappeared after treatment.
In 15 out of 21 cases there was no evidence of residual cyst on US, computed tomography (CT) or
magnetic resonance (MRI). In 6 patients with shorter follow-up, cysts showed a mean reduction
in diameter of 50%. The mean follow-up was 18 months (range 6–60 months).We conclude that PAS is easy with low risk for the patients and with good long-term results; it
should therefore become the procedure of choice for simple hepatic cysts. 相似文献
34.
35.
Dr. A. Belluzzi MD C. Brignola MD M. Campieri MD E. P. Camporesi BS P. Gionchetti MD F. Rizzello MD C. Belloli MD G. De Simone MD S. Boschi MD M. Miglioli MD L. Barbara MD 《Digestive diseases and sciences》1994,39(12):2589-2594
Fish oil has been recently proposed as a possible effective treatment in inflammatory bowel disease (IBD); however, a lot of annoying side effects (ie, belching, halitosis, diarrhea, etc) affect patient compliance. We carried out a study of patient tolerance in a group of Crohn's disease (CD) patients with a new fish oil derivative consisting of 500-mg capsules of eicosapentaenoic-docosahexaenoic (EPA 40%-DHA 20%), a free fatty acid mixture (Purepa), and we also evaluated its incorporation into phospholipids, both in plasma and in red cell membranes. Five groups of 10 CD patients in remission received nine Purepa capsules daily in four different preparations (A: uncoated, B: coated, pH 5.5; C: coated, pH 5.5, 60 min time release; D: coated, pH 6.9) and 12 × 1-g capsules daily of a triglyceride preparation (Max-EPA, EPA 18%-DHA 10%), respectively. We coated three of the four Purepa preparations in order to delay the release of contents in an attempt to minimize the side effects. After six weeks of treatment, the group taking Purepa capsules, coated, pH 5.5, 60 min time release (group C) showed the best incorporation of EPA and DHA in red blood cell phospholipid membranes (EPA from 0.2 to 4.4%, DHA from 3.7 to 6.3%), and no side effects were registered, whereas in all other groups side effects were experienced in 50% or more of subjects. This new preparation will make it possible to treat patients for long periods. 相似文献
36.
Priv.-Doz. Dr. J. E. Hoppe cand. med. Simone Köster Prof. Dr. D. Niethammer Priv.-Doz. Dr. F. Bootz 《Infection》1994,22(3):178-182
Summary During recent years, a significantly increased incidence of acute mastoiditis was observed at the University Children's Hospital, Tübingen, Germany (1975–1979: 1.4 patients/year; 1987–1992: 4.2 patients/year; p<0.05). We therefore reviewed the records of all patients with acute mastoiditis (n=58) that had been treated at the Children's Hospital between 1975 and 1992 and at the Clinic of Otorhinolaryngology between 1978 and 1992. The male to female ratio was 1.8:1 and 60.4% of the patients were younger than 24 months. Retroauricular swelling was more often observed (n=49) than protrusion of the pinna (n=45) and retroauricular redness (n=38).Streptococcus pneumoniae was the most frequently isolated pathogen. Several factors predisposing for the development of acute mastoiditis were identified. These included withholding antimicrobials for treatment of the preceding episode of otitis media; use of suboptimal agents for therapy of otitis media (penicillin and, possibly, erythromycin ethylsuccinate); and insufficient duration of treatment.
Akute Mastoiditis — wieder ein aktuelles Problem
Zusammenfassung In den letzten Jahren wurde an der Univ.-Kinderklinik Tübingen eine signifikante Zunahme der Inzidenz der akuten Mastoiditis beobachtet (1975–1979: 1,4 Patienten/Jahr; 1987–1992: 4,2 Patienten/Jahr; p<0,05). Wir analysierten daher die Krankengeschichten aller Patienten mit akuter Mastoiditis (n=58), die zwischen 1975 und 1992 an der Universitäts-Kinderklinik und zwischen 1978 und 1992 an der Universitäts-Hals-Nasen-Ohrenklinik behandelt worden waren. Das Verhältnis von Jungen zu Mädchen betrug 1,8:1, und 60,4% der Patienten waren jünger als 24 Monate. Eine retroaurikuläre Schwellung wurde häufiger beobachtet (n=48) als ein abstehendes Ohr (n=45) und eine retroaurikuläre Rötung (n=38).Streptococcus pneumoniae war der häufigste Erreger. Mehrere für das Auftreten einer akuten Mastoiditis prädisponierende Faktoren wurden gefunden: die Nichtbehandlung der vorausgegangenen Otitis media mit Antibiotika, der Einsatz suboptimaler Antibiotika (Penicillin und möglicherweise Erythromycin-Ethylsuccinat) für die Otitis-Behandlung und eine ungenügende Therapiedauer.相似文献
37.
38.
M Grimm E Eybl M Grabenw?ger H Spreitzer W J?ger G Grimm P B?ck M M Müller E Wolner 《Surgery》1992,111(1):74-78
A marked release of glutaraldehyde from commercially available pericardial bioprosthetic heart valve (BHV) material in washing solutions was found by high performance liquid chromatography (up to 1.8 ppm of glutaraldehyde per gram of dry tissue). In vitro endothelial cell proliferation rate was impaired dose-dependently in the presence of increasing glutaraldehyde concentrations of the cultivation medium (r = 0.9; p less than 0.05). Cultivation of endothelial cells was impossible on the surface of commercially available BHV material, but successful and uninhibited when toxic glutaraldehyde ligands of the BHV material were antagonized by treatment with L-glutamic acid. 相似文献
39.
Daniel Zimpfer Philipp Zrunek Sigrid Sandner Heinz Schima Michael Grimm Andreas Zuckermann Ernst Wolner Georg Wieselthaler 《European journal of cardio-thoracic surgery》2007,31(4):698-702
OBJECTIVE: We have previously shown that fixed pulmonary hypertension in cardiac transplant candidates can be lowered using left ventricular assist devices (LVADs). The post-transplant survival of these patients is uncertain as pulmonary hypertension may reappear, possibly affecting post-transplant survival. MATERIALS AND METHODS: Between 01/2000 and 01/2005 a total of 26 cardiac transplant candidates (92% male; mean age 56.2 years) in whom fixed pulmonary hypertension was lowered by LVAD implantation (pulmonary vascular resistance (PVR) before implantation: 5.1+/-2.8wood units (WU); PVR before cardiac transplantation: 2.0+/-.9WU) underwent cardiac transplantation at our institution. These patients were age and sex matched with 52 cardiac transplant candidates without pulmonary hypertension undergoing cardiac transplantation during the same time period. Study endpoints were peri-transplant complications and long-term survival. Mean follow-up was 36+/-14 months. RESULTS: Peri-transplant mortality was 5% in patients after LVAD therapy and 7% in patients without prior LVAD therapy (p=.089). We observed 2 cases (4%) of acute right heart failure requiring mechanical support in patients without prior LVAD therapy. None of the patients with LVAD therapy developed peri-transplant right heart failure requiring mechanical support. Incidence of other peri-transplant complications was comparable between the two groups. Log-rank (p=.124) revealed comparable long-term survival between patients with (1 year: 85%, 2 year: 85%, 3 year: 85%) and without (1 year: 90%, 2 year 82%, 3 year prior 79%) prior LVAD therapy. CONCLUSION: LVAD therapy lowers fixed pulmonary hypertension in cardiac transplant candidates with fixed pulmonary hypertension. Thereafter, long-term post-transplant survival is comparable to cardiac transplant recipients without pulmonary hypertension. 相似文献
40.
Serge Evrard Yves Bécouarn René Brunet Marianne Fonck Caroline Larrue Simone Mathoulin-Pélissier 《Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie》2007,392(1):41-44
BACKGROUND AND AIMS: The aim of this work was to test the feasibility of using a bipolar low thermal acting system inducing collagenic sealing but not protein coagulation to secure hepatic parenchyma cutting. MATERIALS AND METHODS: Thirty consecutive hepatectomies were carried out using kellyclasy plus ligatures and clips (controls), while the following 50 hepatectomies used kellyclasy plus bipolar vessels sealer (BVS). Blood loss, duration of hepatic pedicle clamping, length of hospital stay, and complications were recorded. RESULTS: There was no statistically significant difference in blood loss and duration of clamping between controls and BVS. Specific complications (9/21 in the control group vs 1/49 for the BVS group, p<0.00045) and length of hospital stay (14 days in the control group vs 11 days in the BVS group, p<0.014) were statistically lower in BVS group than in the controls, mainly due to prevention of bile duct leakages. CONCLUSIONS: Our data suggest that BVS may be particularly efficient to achieve bilistasis leading to the highest level of safety in performing hepatectomies. Further studies are now needed to confirm its superiority on the classical biliary ducts occlusion techniques. 相似文献